Economic impacts of overweight and obesity: current and future estimates for eight countries
Adeyemi Okunogbe(RAND Corporation), John Wilding(University of Liverpool)
Cited by 363
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
Definition and diagnostic criteria of clinical obesity
|The Lancet Diabetes & Endocrinology|2025|1.3k
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
|The Lancet|2017|843
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
|The Lancet Diabetes & Endocrinology|2019|673